Esperion Therapeutics (NASDAQ:ESPR) is set to post its quarterly earnings results before the market opens on Tuesday, February 20th. Analysts expect Esperion Therapeutics to post earnings of ($1.80) per share for the quarter.

Esperion Therapeutics (NASDAQ ESPR) opened at $68.22 on Tuesday. Esperion Therapeutics has a 12 month low of $19.90 and a 12 month high of $82.18. The firm has a market cap of $1,750.00, a P/E ratio of -9.94 and a beta of 2.64.

A number of research analysts have recently weighed in on the stock. ValuEngine raised shares of Esperion Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, February 2nd. Citigroup cut shares of Esperion Therapeutics from a “buy” rating to a “neutral” rating and raised their price objective for the stock from $77.00 to $96.00 in a research note on Monday, January 22nd. BidaskClub cut shares of Esperion Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, December 7th. Bank of America raised shares of Esperion Therapeutics from a “neutral” rating to a “buy” rating and set a $76.00 price objective for the company in a research note on Friday, January 5th. Finally, Chardan Capital reissued a “neutral” rating and set a $75.00 price objective (up from $20.00) on shares of Esperion Therapeutics in a research note on Tuesday, December 5th. Six investment analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have given a strong buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of $77.23.

In other Esperion Therapeutics news, Director Nicole Vitullo sold 11,674 shares of Esperion Therapeutics stock in a transaction that occurred on Thursday, January 25th. The shares were sold at an average price of $71.79, for a total value of $838,076.46. Following the completion of the sale, the director now directly owns 3,177 shares of the company’s stock, valued at approximately $228,076.83. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 32.50% of the stock is currently owned by insiders.

WARNING: “Esperion Therapeutics (ESPR) to Release Earnings on Tuesday” was posted by TheOlympiaReport and is the property of of TheOlympiaReport. If you are viewing this article on another site, it was illegally copied and reposted in violation of US & international trademark & copyright laws. The correct version of this article can be read at https://theolympiareport.com/2018/02/13/esperion-therapeutics-espr-to-release-earnings-on-tuesday.html.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company’s lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects.

Earnings History for Esperion Therapeutics (NASDAQ:ESPR)

Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.